GALT
Price
$1.28
Change
-$0.04 (-3.03%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
81.19M
45 days until earnings call
NVO
Price
$67.12
Change
-$1.12 (-1.64%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
299.64B
33 days until earnings call
Ad is loading...

GALT vs NVO

Header iconGALT vs NVO Comparison
Open Charts GALT vs NVOBanner chart's image
Galectin Therapeutics
Price$1.28
Change-$0.04 (-3.03%)
Volume$785
Capitalization81.19M
Novo-Nordisk A/S
Price$67.12
Change-$1.12 (-1.64%)
Volume$42.27K
Capitalization299.64B
GALT vs NVO Comparison Chart
Loading...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GALT vs. NVO commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GALT is a StrongBuy and NVO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (GALT: $1.28 vs. NVO: $67.10)
Brand notoriety: GALT and NVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GALT: 122% vs. NVO: 114%
Market capitalization -- GALT: $81.19M vs. NVO: $299.64B
GALT [@Biotechnology] is valued at $81.19M. NVO’s [@Biotechnology] market capitalization is $299.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GALT’s FA Score shows that 0 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).

  • GALT’s FA Score: 0 green, 5 red.
  • NVO’s FA Score: 2 green, 3 red.
According to our system of comparison, NVO is a better buy in the long-term than GALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GALT’s TA Score shows that 5 TA indicator(s) are bullish while NVO’s TA Score has 4 bullish TA indicator(s).

  • GALT’s TA Score: 5 bullish, 4 bearish.
  • NVO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GALT is a better buy in the short-term than NVO.

Price Growth

GALT (@Biotechnology) experienced а -23.51% price change this week, while NVO (@Biotechnology) price change was -2.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

GALT is expected to report earnings on May 19, 2025.

NVO is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($300B) has a higher market cap than GALT($81.2M). GALT YTD gains are higher at: 2.326 vs. NVO (-20.738). NVO has higher annual earnings (EBITDA): 137B vs. GALT (-40.38M). NVO has higher revenues than GALT: NVO (290B) vs GALT (0).
GALTNVOGALT / NVO
Capitalization81.2M300B0%
EBITDA-40.38M137B-0%
Gain YTD2.326-20.738-11%
P/E RatioN/A20.50-
Revenue0290B-
Total Cash27.1MN/A-
Total Debt105MN/A-
FUNDAMENTALS RATINGS
GALT vs NVO: Fundamental Ratings
GALT
NVO
OUTLOOK RATING
1..100
8655
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
10015
PRICE GROWTH RATING
1..100
8789
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVO's Valuation (25) in the Pharmaceuticals Major industry is significantly better than the same rating for GALT (97) in the Biotechnology industry. This means that NVO’s stock grew significantly faster than GALT’s over the last 12 months.

NVO's Profit vs Risk Rating (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for GALT (100) in the Biotechnology industry. This means that NVO’s stock grew somewhat faster than GALT’s over the last 12 months.

NVO's SMR Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for GALT (100) in the Biotechnology industry. This means that NVO’s stock grew significantly faster than GALT’s over the last 12 months.

GALT's Price Growth Rating (87) in the Biotechnology industry is in the same range as NVO (89) in the Pharmaceuticals Major industry. This means that GALT’s stock grew similarly to NVO’s over the last 12 months.

NVO's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as GALT (100) in the Biotechnology industry. This means that NVO’s stock grew similarly to GALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GALTNVO
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 17 days ago
67%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 7 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
54%
View a ticker or compare two or three
Ad is loading...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WU10.50-0.13
-1.22%
Western Union Company (The)
GROY1.39-0.02
-1.42%
Gold Royalty Corp
NXPL0.77-0.02
-2.95%
NextPlat Corp
DEA10.25-0.34
-3.21%
Easterly Government Properties
DDOG94.47-7.24
-7.12%
Datadog

GALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
+4.76%
BCAB - GALT
35%
Loosely correlated
-3.88%
SNPX - GALT
32%
Poorly correlated
-2.56%
RNAC - GALT
32%
Poorly correlated
+3.68%
NVO - GALT
31%
Poorly correlated
+0.31%
ERAS - GALT
27%
Poorly correlated
+4.56%
More

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-1.67%
NONOF - NVO
70%
Closely correlated
-1.59%
GALT - NVO
34%
Loosely correlated
-2.65%
BCAB - NVO
32%
Poorly correlated
-11.66%
AXON - NVO
29%
Poorly correlated
-3.35%
LABFF - NVO
29%
Poorly correlated
N/A
More